Innovent Biologics Aosaikang Pharmaceutical makes efforts in both independent research and development and
introduction and cooperation, focusing on the research and development of innovative small molecule
target drugs and innovative tumor immunobiological drugs. There are currently 48 major projects
under research, including 11 publicly available whatsapp number list key projects of innovative chemical and biological drugs.
Among them, the innovative antitumor drug Liertinib Tablets is in the stage of applying for listing,
ASKC109 (maltol iron capsules and ASKB589 (Claudin18.2 monoclonal antibody are in the phase III
clinical research stage, and many other innovative drugs are in the early clinical and preclinical research stages.
Aosaikang Pharmaceutical adheres to the corporate mission
Of “acting for health”, targets urgent and unmet clinical nes, sticks to its original aspirations, moves
forward, accelerates the transformation of innovative achievements into real productivity, develops
and launches more domestically produc highquality new drugs and good drugs, and contributes
Aosaikang’s strength to improve the machine-to-machine communication and iiot accessibility, advancement and sustainability of patients’ micines and to the highquality development of the biopharmaceutical industry.
For more information, please visit the company website: .askpharm
The information contain in this press release may contain certain forwardlooking statements
These statements are inherently subject to considerable risks and uncertainties. When us in
conjunction with the Company, the words “anticipate,” “believe,” “forecast,” “expect,” “intend” and
other similar expressions are intend to identify forwardlooking statements. The Company undertakes
no obligation to continually update these forwardlooking statements.
These forwardlooking statements are bas on the current views, assumptions, expectations, estimates,
projections and perceptions of the Company’s trust review management regarding future events at the time the statements are made. These statements are not guarantees of future development and are subject to risks, uncertainties and other factors, some of which are beyond the control of the Company and are difficult to prict. Therefore, actual results may differ materially from those contain in the forwardlooking statements due to future changes and developments in our business, competitive environment, political, economic, legal and social conditions Innovent Biologics.